Expression of nm23-H1, p53, and integrin β1 in endometriosis and their clinical significance.
Nm23-H1
endometriosis
estrogen
integrin β1
p53
Journal
International journal of clinical and experimental pathology
ISSN: 1936-2625
Titre abrégé: Int J Clin Exp Pathol
Pays: United States
ID NLM: 101480565
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
02
2020
accepted:
27
03
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
To investigate the expression and clinical significance of nucleoside diphosphate kinase A (nm23-H1), p53, and integrin β1 in endometriosis, normal and ectopic endometrial tissues were collected and the levels of nm23-H1, p53, and integrin β1 proteins were detected by western blotting. We also measured the mRNA expression of nm23-H1, p53, and integrin β1 in endometrial epithelial cells by droplet digital PCR, based on endometrial tissues using laser capture microdissection. Moreover, primary stromal cells from normal and ectopic endometrial tissues were also cultured and treated with different concentrations of estrogen. We assessed the mRNA levels of nm23-H1, p53, and integrin β1 by quantitative PCR. Compared with normal endometrial tissue, the levels of nm23-H1 and p53 proteins were significantly downregulated in ectopic endometrial tissues, while integrin β1 protein was upregulated. The same expression trend in the mRNA levels of nm23-H1, p53, and integrin β1 was also observed in both endometrial epithelial cells and stromal cells. In addition, with increasing estrogen concentration, nm23-H1 and p53 mRNA levels gradually decreased, while integrin β1 mRNA expression increased. Nm23-H1 and p53 may inhibit the progression of endometriosis, while integrin β1 has a promoting effect, and estrogen is involved in this process.
Types de publication
Journal Article
Langues
eng
Pagination
1024-1029Informations de copyright
IJCEP Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
BMC Res Notes. 2018 Oct 11;11(1):722
pubmed: 30309386
Naunyn Schmiedebergs Arch Pharmacol. 2015 Feb;388(2):175-87
pubmed: 25366701
Int J Surg Case Rep. 2013;4(2):160-3
pubmed: 23276756
Hum Reprod. 2019 May 1;34(5):813-823
pubmed: 31067329
Int J Womens Health. 2019 Jul 23;11:405-410
pubmed: 31413643
Best Pract Res Clin Obstet Gynaecol. 2018 Aug;51:1-15
pubmed: 30017581
Biochem Biophys Res Commun. 2013 May 10;434(3):541-6
pubmed: 23583378
BMC Cancer. 2018 Jul 3;18(1):710
pubmed: 29970055
Hum Reprod. 2007 Dec;22(12):3159-69
pubmed: 17956924
Gynecol Oncol Rep. 2019 Jan 04;28:23-25
pubmed: 30805426
Gynecol Obstet Fertil Senol. 2018 Mar;46(3):156-167
pubmed: 29540335
Reproduction. 2010 Apr;139(4):799-808
pubmed: 20145075
Gynecol Obstet Fertil Senol. 2017 Jul - Aug;45(7-8):393-399
pubmed: 28712793
J Reprod Immunol. 2006 Jun;70(1-2):151-62
pubmed: 16378643
Hum Reprod. 2013 Oct;28(10):2822-31
pubmed: 23856325
Front Oncol. 2019 Jul 24;9:538
pubmed: 31428569
Nat Rev Dis Primers. 2018 Jul 19;4(1):9
pubmed: 30026507
Int J Med Sci. 2018 Oct 20;15(13):1530-1536
pubmed: 30443175
Clin Exp Metastasis. 2013 Jan;30(1):25-36
pubmed: 22699362
J Clin Endocrinol Metab. 2013 Feb;98(2):E238-48
pubmed: 23293332
Int J Surg Case Rep. 2013;4(1):54-7
pubmed: 23124069
Semin Reprod Med. 2017 May;35(3):263-270
pubmed: 28658710
Oncol Lett. 2017 Jan;13(1):129-136
pubmed: 28123532
Mol Med Rep. 2018 Nov;18(5):4410-4416
pubmed: 30152851
J Biol Chem. 2007 Nov 30;282(48):35293-307
pubmed: 17916563
PLoS One. 2019 Aug 1;14(8):e0220529
pubmed: 31369616
PLoS One. 2014 Mar 21;9(3):e92687
pubmed: 24658123
Int J Mol Sci. 2019 Aug 05;20(15):
pubmed: 31387263